Latest news with #FrenchCommercialCode
Business Wire
24-06-2025
- Business
- Business Wire
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16 th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law. In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314. This document is available on the Company's website at: *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS C Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D.25-0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
24-06-2025
- Business
- Yahoo
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France, June 24, 2025--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law. In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314. This document is available on the Company's website at: *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB1-SSi in humans. The Company also has a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB1-SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4Ticker: AELISC Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D.25-0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements. View source version on Contacts AELIS FARMA Pier Vincenzo PiazzaChief Executive Officercontact@ NewCap Dusan Oresansky / Aurélie ManavarereInvestor Relationsaelis@ +33 1 44 71 94 92 NewCap Arthur RouilléMedia Relationsaelis@ +33 1 44 71 00 15 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025 Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution). This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052. This document can be consulted on the Company's investor relations website ( For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 Or visit our website: Attachment PDF
Yahoo
17-06-2025
- Business
- Yahoo
QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025 Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution). This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052. This document can be consulted on the Company's investor relations website ( For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 Or visit our website: Attachment PDFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-06-2025
- Business
- Yahoo
Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers
InformationJune 16, 2025 Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Information relating to the total number of shares and voting rights comprising the share capital as of May 31, 2025 Date Total number of shares1 comprising the share capital Theoretical number of voting rights2 05/31/2025 179,389,135 179,389,135 * * * SCOR, a leading global reinsurer As a leading global reinsurer, SCOR offers its clients a diversified and innovative range of reinsurance and insurance solutions and services to control and manage risk. Applying 'The Art & Science of Risk', SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society. The Group generated premiums of EUR 20.1 billion in 2024 and serves clients in more than 150 countries from its 37 offices worldwide. For more information, visit: Media Relations Alexandre Garciamedia@ Investor RelationsThomas FossardInvestorRelations@ Follow us on LinkedIn All content published by the SCOR group since January 1, 2024, is certified with Wiztrust. You can check the authenticity of this content at 1 Each at a nominal value of EUR 7.87697232 The gross number of voting rights is calculated on the basis of all shares carrying voting rights, including shares whose voting rights have been suspended (Art. 223-11 of the General Regulation of the AMF) Attachment SCOR InformationError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
